中文Vientiane, Laos - April 8, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos.
Approved drugs are:
Selumetinib: sold under the brand name SEMEDX. Selumetinib was approved for marketing in the United States on April 10, 2020. It is suitable for children aged 2 years and above with neurofibromatosis type 1 (NF1) to treat inoperable plexiform neurofibromas (PN). patient. Selumetinib is a kinase inhibitor (TKI) targeting MEK, a key protein kinase in the RAS/MAPK signaling pathway. Selumetinib can selectively inhibit MEK1 and MEK2, thereby normalizing dysregulated signaling pathways.
Lao registered trade name: Lao Reg No.: 03L1085/24
Baricitinib: Sold under the brand name BARUDX. Baricitinib is a selective, reversible JAK1 and JAK2 inhibitor that is taken orally once daily and is currently in clinical development for the treatment of a variety of inflammatory and autoimmune diseases, including rheumatoid arthritis ( RA), ankylosing spondylitis (AS), psoriasis (psoriasis), atopic dermatitis, systemic lupus erythematosus, ulcerative enteritis (UC), alopecia areata, etc.
Lao registered trade name: Lao Reg No.: 03L1083/24 2mg
Lao registered trade name: Lao Reg No.: 03L1084/24 4mg
About BigBear Pharmaceuticals:
BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.
Forward-Looking Statements:
Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.